S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:IMGN - ImmunoGen Stock Price, Forecast & News

$3.55
-0.15 (-4.05 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$3.41
Now: $3.55
$3.77
50-Day Range
$2.12
MA: $4.29
$6.80
52-Week Range
$1.76
Now: $3.55
$7.07
Volume2.58 million shs
Average Volume3.54 million shs
Market Capitalization$618.84 million
P/E RatioN/A
Dividend YieldN/A
Beta2.47
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Read More
ImmunoGen logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IMGN
CUSIP45253H10
Phone781-895-0600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$82.27 million
Book Value($0.51) per share

Profitability

Net Income$-104,130,000.00
Net Margins-126.57%

Miscellaneous

Employees296
Market Cap$618.84 million
Next Earnings Date5/1/2020 (Estimated)
OptionableOptionable

Receive IMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter.


ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

How has ImmunoGen's stock been impacted by COVID-19 (Coronavirus)?

ImmunoGen's stock was trading at $3.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IMGN shares have increased by 5.3% and is now trading at $3.55. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ImmunoGen?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ImmunoGen.

When is ImmunoGen's next earnings date?

ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, May 1st 2020. View our earnings forecast for ImmunoGen.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings data on Friday, February, 14th. The biotechnology company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.08. The biotechnology company earned $44.86 million during the quarter, compared to analysts' expectations of $29.24 million. View ImmunoGen's earnings history.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen updated its FY 2020 Pre-Market earnings guidance on Friday, February, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $60-65 million, compared to the consensus revenue estimate of $44.62 million.

What price target have analysts set for IMGN?

4 Wall Street analysts have issued 12-month price objectives for ImmunoGen's shares. Their forecasts range from $2.94 to $9.00. On average, they expect ImmunoGen's share price to reach $5.97 in the next twelve months. This suggests a possible upside of 68.2% from the stock's current price. View analysts' price targets for ImmunoGen.

Has ImmunoGen been receiving favorable news coverage?

News articles about IMGN stock have trended very negative on Monday, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ImmunoGen earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutImmunoGen.

Who are some of ImmunoGen's key competitors?

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Immunomedics (IMMU), Micron Technology (MU), Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Exelixis (EXEL), Nektar Therapeutics (NKTR), Sangamo Therapeutics (SGMO) and Alibaba Group (BABA).

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the following people:
  • Mr. Mark J. Enyedy, Pres, CEO, Interim Principal Financial Officer & Director (Age 55)
  • Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 61)
  • Mr. Craig Barrows, Exec. VP, Gen. Counsel & Sec. (Age 64)
  • Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 49)
  • Mr. David G. Foster, VP of Fin. & Chief Accounting Officer

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (7.15%), Palo Alto Investors LP (3.96%), State Street Corp (3.57%), Geode Capital Management LLC (1.62%), Panagora Asset Management Inc. (1.41%) and Pinnacle Associates Ltd. (0.85%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Craig Barrows, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy, Richard J Gregory and Thomas Ryll. View institutional ownership trends for ImmunoGen.

Which major investors are selling ImmunoGen stock?

IMGN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, SG Americas Securities LLC, Rafferty Asset Management LLC, Bank of America Corp DE, Pinnacle Associates Ltd., Stifel Financial Corp, and Raymond James & Associates. Company insiders that have sold ImmunoGen company stock in the last year include Craig Barrows, Mark J Enyedy, and Thomas Ryll. View insider buying and selling activity for ImmunoGen.

Which major investors are buying ImmunoGen stock?

IMGN stock was purchased by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Renaissance Technologies LLC, FMR LLC, Goldman Sachs Group Inc., Panagora Asset Management Inc., Public Sector Pension Investment Board, Jacobs Levy Equity Management Inc., and Los Angeles Capital Management & Equity Research Inc.. View insider buying and selling activity for ImmunoGen.

How do I buy shares of ImmunoGen?

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $3.55.

How big of a company is ImmunoGen?

ImmunoGen has a market capitalization of $618.84 million and generates $82.27 million in revenue each year. The biotechnology company earns $-104,130,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. ImmunoGen employs 296 workers across the globe. View additional information about ImmunoGen.

What is ImmunoGen's official website?

The official website for ImmunoGen is http://www.immunogen.com/.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]


MarketBeat Community Rating for ImmunoGen (NASDAQ IMGN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  430 (Vote Outperform)
Underperform Votes:  472 (Vote Underperform)
Total Votes:  902
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe IMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel